Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-06-10
2008-06-10
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S407000, C549S401000
Reexamination Certificate
active
07384976
ABSTRACT:
The invention describes novel compositions comprising nebivolol and/or at least one metabolite of nebivolol and at least one nitric oxide donor, and, optionally, at least one antioxidant or a pharmaceutically acceptable salt thereof, and/or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and/or at least one nitrosated compound used to treat cardiovascular diseases. The compounds and compositions of the invention can also be bound to a matrix. The nitric oxide donor is a compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The invention also provides methods for treating and/or preventing vascular diseases characterized by nitric oxide insufficiency; and for treating and/or preventing Raynaud's syndrome; and for treating and/or preventing cardiovascular diseases or disorders.
REFERENCES:
patent: 4654362 (1987-03-01), Van Lommen et al.
patent: 5759580 (1998-06-01), Jans et al.
patent: 5874461 (1999-02-01), de Chaffoy de Courcelles et al.
patent: 6075046 (2000-06-01), de Chaffoy de Courcelles et al.
patent: 6635273 (2003-10-01), Loscalzo et al.
patent: WO-95/22325 (1995-08-01), None
patent: WO-96/19987 (1996-07-01), None
patent: WO-98/21193 (1998-05-01), None
patent: WO-99/00361 (1999-01-01), None
patent: WO-99/67231 (1999-12-01), None
patent: WO-00/49993 (2000-08-01), None
patent: WO-00/51988 (2000-08-01), None
patent: WO-00/51978 (2000-09-01), None
patent: WO-00/61537 (2000-10-01), None
patent: WO-00/61541 (2000-10-01), None
patent: WO-00/61549 (2000-10-01), None
patent: WO-00/67754 (2000-11-01), None
patent: WO-01/12584 (2001-02-01), None
patent: WO-02/051385 (2002-07-01), None
patent: 2005/053685 (2005-06-01), None
patent: 2005/054218 (2005-06-01), None
Broeders, M.A.W. et al.: Nebivolol : A third generation beta-blocker that augments vascular nitric oxide release. Circulation, vol. 102, pp. 677-684, 2000.
International Search Report for PCT/US02/13667. (Jun. 5, 2003).
Aulakh Charanjit S.
NitroMed Inc.
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Nebivolol and its metabolites in combination with nitric... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nebivolol and its metabolites in combination with nitric..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nebivolol and its metabolites in combination with nitric... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2812339